The Allen Institute for Immunology, a division of the Seattle-based Allen Institute, is teaming with Seattle Children’s Research Institute to launch a study aimed at understanding the origins of inflammatory bowel disorder (IBD), the organizations announced Monday.
The new initiative, called the Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE) study, will be a first-of-its-kind pediatric study. Researchers will use state-of-the-art technology to understand how genes and other molecules behave in individual cells of patients who haven’t been treated yet.
IBD — which includes Crohn’s disease and ulcerative colitis — affects 3 million people in the United States and 30% of all IBD diagnoses are in patients 20 years and younger. Seattle Children’s said the incidence of IBD is around 10.9 per 100,000 children and growing over recent years.